Merck, Bristol-Myers tout hepatitis C drugs at key AASLD meeting
This article was originally published in Scrip
Merck & Co and Bristol-Myers Squibb are making their best cases yet to show they’re serious contenders in a race to sell improved treatments for hepatitis C, the virus that destroys the liver and chronically infects millions.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.